Type 2 diabetes will lead insulin pens sales through 2036 with 67.0% of the indication segment in 2026. Reusable insulin pens dominate the product segment with a 53.0% share. The market is expected to reach USD 42.0 billion in 2026 and USD 75.17 billion by 2036 across global diabetes care.